News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
May 16, 2019DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019Printer Friendly Version
May 07, 2019DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a TrialPrinter Friendly Version
May 07, 2019DURECT Corporation Announces First Quarter 2019 Financial Results and Update of ProgramsPrinter Friendly Version
May 03, 2019DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial ResultsPrinter Friendly Version
Apr 25, 2019DURECT Appoints Two New Board MembersPrinter Friendly Version
Apr 01, 2019DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASHPrinter Friendly Version
Mar 27, 2019DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)Printer Friendly Version
Mar 21, 2019DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque PsoriasisPrinter Friendly Version
Mar 07, 2019DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of ProgramsPrinter Friendly Version
Mar 04, 2019DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference CallPrinter Friendly Version
Feb 27, 2019DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response LetterPrinter Friendly Version
Feb 21, 2019DURECT Corporation to Participate in the Berenberg NASH DayPrinter Friendly Version
Jan 07, 2019DURECT Corporation Provides Corporate UpdatePrinter Friendly Version
Jan 03, 2019DURECT Corporation Announces Investor Call to Provide Corporate UpdatePrinter Friendly Version